Induced pluripotent stem cells derived brain endothelial cells from patients suffering from familial form of Alzheimer’s disease display impaired barrier function and cell metabolism
Preprint
- 4 November 2020
- preprint
- Published by Springer Nature in Research Square
Abstract
Background: Alzheimer’s disease (AD) is the most common form of neurodegenerative disease. It is an irreversible condition marked by irreversible cognitive loss, commonly attributed to the loss of hippocampal neurons due to the formation of senile plaques and neurofibrillary tangles. Although the sporadic form is the most prevalent, the presence of familial form (involving several genes such as APP, PSEN1 and PSEN2) of the disease is commonly used as a model for understanding the pathophysiology of the disease. The aim of this study is to investigate the effect of mutation on PSEN1 and PSEN2 genes on the BBB function using induced pluripotent stem cells (iPSCs).Methods: iPSC lines from patients suffering from familial form of Alzheimer’s disease and harboring mutations in PSEN1 or PSEN2 were used in this study and compared to a control iPSC line. Cells were differentiated into brain microvascular endothelial cells (BMECs) following established differentiation protocols. Barrier function was assessed by measuring TEER and fluorescein permeability, drug transporters activity was assessed by uptake assay, glucose uptake and metabolism assessed by cell flux analyzer, mitochondrial potential by JC-1 and lysosomal acidification by acridine orange. Results: iPSC derived BMECs from the FAD patient presenting a mutation in PSEN1 gene showed impaired barrier function compared to the FAD patient harboring a mutation in PSEN2 and to control group. Such impaired barrier function correlated with poor tight junction complexes and reduced drug efflux pump activity. In addition, both PSEN1 and PSEN2-BMECs displayed reduced bioenergetics, lysosomal acidification, autophagy, while showing an increase in radical oxygen species (ROS) production. Finally, PSEN1- and PSEN2-BMECs showed an elevated secretion of Ab1-40 peptides compared to control-BMECs.Conclusion: Our study reports that iPSC-derived BMECs obtained from FAD patients showed impaired barrier properties and BMECs metabolism. In particular, PSEN1 mutation was associated with a more detrimental phenotype than the PSEN2 mutation, as noted by a reduced barrier function, reduced drug efflux pump activity and diminished glucose metabolism. Therefore, assessing the contribution of genetic mutations associated with Alzheimer’s disease will allow us to better understand the contribution of the BBB in dementia, but also other neurodegenerative diseases.Keywords
All Related Versions
- Published version: Fluids and Barriers of the CNS, 18 (1), 1.
This publication has 32 references indexed in Scilit:
- Autophagy Induction by Bexarotene Promotes Mitophagy in Presenilin 1 Familial Alzheimer’s Disease iPSC-Derived Neural Stem CellsMolecular Neurobiology, 2019
- Vascular dysfunction—The disregarded partner of Alzheimer's diseaseAlzheimer's & Dementia, 2019
- Generation of a human induced pluripotent stem cell–based model for tauopathies combining three microtubule‐associated protein TAU mutations which displays several phenotypes linked to neurodegenerationAlzheimer's & Dementia, 2018
- Tau Proteins and Tauopathies in Alzheimer’s DiseaseCellular and Molecular Neurobiology, 2018
- Regulatory effects of simvastatin and apoJ on APP processing and amyloid-β clearance in blood-brain barrier endothelial cellsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2018
- Molecular mechanism of prion‐like tau‐induced neurodegenerationAlzheimer's & Dementia, 2016
- GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degenerationNature Neuroscience, 2015
- Derivation of blood-brain barrier endothelial cells from human pluripotent stem cellsNature Biotechnology, 2012
- Recent rodent models for Alzheimer’s disease: clinical implications and basic researchJournal of Neural Transmission, 2011
- Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer diseaseNeuroscience Letters, 2001